{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:50:29Z","timestamp":1777103429909,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,31]]},"DOI":"10.7759\/cureus.85131","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T14:07:50Z","timestamp":1748700470000},"source":"Crossref","is-referenced-by-count":1,"title":["Role of Methylphenidate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Series"],"prefix":"10.7759","author":[{"given":"Varchasvi","family":"Mudgal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloni","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upma","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koustubh R","family":"Bagul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19ac13182","article-title":"Pharmacotherapy for treatment-resistant obsessive-compulsive disorder","volume":"81","author":"Kayser RR","year":"2020","unstructured":"Kayser RR. Pharmacotherapy for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2020, 81:19. 10.4088\/JCP.19ac13182","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2020_204","article-title":"Pharmacotherapeutic strategies and new targets in OCD","volume":"49","author":"Pittenger C","year":"2021","unstructured":"Pittenger C. Pharmacotherapeutic strategies and new targets in OCD. Curr Top Behav Neurosci. 2021, 49:331-84. 10.1007\/7854_2020_204","journal-title":"Curr Top Behav Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.12.010","article-title":"Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: a randomized double-blind, placebo-controlled study","volume":"29","author":"Zheng H","year":"2019","unstructured":"Zheng H, Jia F, Han H, et al.. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: a randomized double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2019, 29:397-404. 10.1016\/j.euroneuro.2018.12.010","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1586\/ern.09.148","article-title":"Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder","volume":"10","author":"Koo MS","year":"2010","unstructured":"Koo MS, Kim EJ, Roh D, Kim CH. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev Neurother. 2010, 10:275-90. 10.1586\/ern.09.148","journal-title":"Expert Rev Neurother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2023.06.003","article-title":"A meta-analysis of transcranial magnetic stimulation in obsessive-compulsive disorder","volume":"8","author":"Steuber ER","year":"2023","unstructured":"Steuber ER, McGuire JF. A meta-analysis of transcranial magnetic stimulation in obsessive-compulsive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023, 8:1145-55. 10.1016\/j.bpsc.2023.06.003","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"ref6","article-title":"Obsessive-Compulsive Disorder","author":"Brock H","year":"2024","unstructured":"Brock H, Rizvi A, Hany M. Obsessive-Compulsive Disorder. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2011.11.003","article-title":"Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways","volume":"16","author":"Milad MR","year":"2012","unstructured":"Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012, 16:43-51. 10.1016\/j.tics.2011.11.003","journal-title":"Trends Cogn Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-014-0146-x","article-title":"The neurobiological link between OCD and ADHD","volume":"6","author":"Brem S","year":"2014","unstructured":"Brem S, Gr\u00fcnblatt E, Drechsler R, Riederer P, Walitza S. The neurobiological link between OCD and ADHD. Atten Defic Hyperact Disord. 2014, 6:175-202. 10.1007\/s12402-014-0146-x","journal-title":"Atten Defic Hyperact Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"Goodman WK","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, et al.. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989, 46:1006-11. 10.1001\/archpsyc.1989.01810110048007","journal-title":"Arch Gen Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700206","article-title":"Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007","volume":"57","author":"Brault MC","year":"2012","unstructured":"Brault MC, Lacourse \u00c9. Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007. Can J Psychiatry. 2012, 57:93-101. 10.1177\/070674371205700206","journal-title":"Can J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2022.152352","article-title":"Treatment-resistant OCD: pharmacotherapies in adults","volume":"120","author":"van Roessel PJ","year":"2023","unstructured":"van Roessel PJ, Grassi G, Aboujaoude EN, Mench\u00f3n JM, Van Ameringen M, Rodr\u00edguez CI. Treatment-resistant OCD: pharmacotherapies in adults. Compr Psychiatry. 2023, 120:152352. 10.1016\/j.comppsych.2022.152352","journal-title":"Compr Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05946-0","article-title":"Methylphenidate for attention-deficit\/hyperactivity disorder in adults: a narrative review","volume":"238","author":"Jaeschke RR","year":"2021","unstructured":"Jaeschke RR, Sujkowska E, Sowa-Ku\u0107ma M. Methylphenidate for attention-deficit\/hyperactivity disorder in adults: a narrative review. Psychopharmacology (Berl). 2021, 238:2667-91. 10.1007\/s00213-021-05946-0","journal-title":"Psychopharmacology (Berl)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2010.06.015","article-title":"Methylphenidate and atomoxetine enhance prefrontal function through \u03b12-adrenergic and dopamine D1 receptors","volume":"49","author":"Gamo NJ","year":"2010","unstructured":"Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through \u03b12-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010, 49:1011-23. 10.1016\/j.jaac.2010.06.015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1124\/pr.114.010397","article-title":"Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease","volume":"67","author":"German CL","year":"2015","unstructured":"German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. Pharmacol Rev. 2015, 67:1005-24. 10.1124\/pr.114.010397","journal-title":"Pharmacol Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109348172","article-title":"Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment","volume":"24","author":"G\u00fcrkan K","year":"2010","unstructured":"G\u00fcrkan K, Bilgi\u00e7 A, T\u00fcrkoglu S, Kili\u00e7 BG, Aysev A, Uslu R. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol. 2010, 24:1810-18. 10.1177\/0269881109348172","journal-title":"J Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.649833","article-title":"Case report: treatment of a comorbid attention deficit hyperactivity disorder and obsessive-compulsive disorder with psychostimulants","volume":"12","author":"Dogan-Sander E","year":"2021","unstructured":"Dogan-Sander E, Strau\u00df M. Case report: treatment of a comorbid attention deficit hyperactivity disorder and obsessive-compulsive disorder with psychostimulants. Front Psychiatry. 2021, 12:649833. 10.3389\/fpsyt.2021.649833","journal-title":"Front Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318290115e","article-title":"Does extended release methylphenidate help adults with hoarding disorder?: a case series","volume":"33","author":"Rodriguez CI","year":"2013","unstructured":"Rodriguez CI, Bender J Jr, Morrison S, Mehendru R, Tolin D, Simpson HB. Does extended release methylphenidate help adults with hoarding disorder?: a case series. J Clin Psychopharmacol. 2013, 33:444-7. 10.1097\/JCP.0b013e318290115e","journal-title":"J Clin Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1039856216671664","article-title":"Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report","volume":"25","author":"King J","year":"2017","unstructured":"King J, Dowling N, Leow F. Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report. Australas Psychiatry. 2017, 25:178-80. 10.1177\/1039856216671664","journal-title":"Australas Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.1.183","article-title":"Dexamphetamine for obsessive-compulsive disorder","volume":"160","author":"Woolley JB","year":"2003","unstructured":"Woolley JB, Heyman I. Dexamphetamine for obsessive-compulsive disorder. Am J Psychiatry. 2003, 160:183. 10.1176\/appi.ajp.160.1.183","journal-title":"Am J Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.05.012","article-title":"Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder","volume":"23","author":"Denys D","year":"2013","unstructured":"Denys D, de Vries F, Cath D, et al.. Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2013, 23:1423-31. 10.1016\/j.euroneuro.2013.05.012","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3746","article-title":"Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective","volume":"15","author":"Pauls DL","year":"2014","unstructured":"Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014, 15:410-24. 10.1038\/nrn3746","journal-title":"Nat Rev Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2008.04.233","article-title":"In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder","volume":"42","author":"Perani D","year":"2008","unstructured":"Perani D, Garibotto V, Gorini A, et al.. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage. 2008, 42:306-14. 10.1016\/j.neuroimage.2008.04.233","journal-title":"Neuroimage"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1017\/S146114571200154X","article-title":"Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity","volume":"16","author":"Sesia T","year":"2013","unstructured":"Sesia T, Bizup B, Grace AA. Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity. Int J Neuropsychopharmacol. 2013, 16:1295-307. 10.1017\/S146114571200154X","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170526120916","article-title":"Promising treatments for obsessive-compulsive disorder: a call for additional research","volume":"25","author":"Koran LM","year":"2018","unstructured":"Koran LM, Aboujaoude E. Promising treatments for obsessive-compulsive disorder: a call for additional research. Curr Med Chem. 2018, 25:5690-7. 10.2174\/0929867324666170526120916","journal-title":"Curr Med Chem"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.11.058","article-title":"Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder","volume":"28","author":"McKay D","year":"2015","unstructured":"McKay D, Sookman D, Neziroglu F, et al.. Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder. Psychiatry Res. 2015, 28:236-46. 10.1016\/j.psychres.2014.11.058","journal-title":"Psychiatry Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.29399\/npa.23654","article-title":"Attention deficit hyperactivity disorder, impulsivity, anxiety, and depression symptoms mediating the relationship between childhood trauma and symptoms severity of obsessive-compulsive disorder","volume":"57","author":"\u00c7oban A","year":"2020","unstructured":"\u00c7oban A, Tan O. Attention deficit hyperactivity disorder, impulsivity, anxiety, and depression symptoms mediating the relationship between childhood trauma and symptoms severity of obsessive-compulsive disorder. Noro Psikiyatr Ars. 2020, 57:37-43. 10.29399\/npa.23654","journal-title":"Noro Psikiyatr Ars"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04605","article-title":"Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"70","author":"Koran LM","year":"2009","unstructured":"Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2009, 70:1530-5. 10.4088\/JCP.08m04605","journal-title":"J Clin Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373836-role-of-methylphenidate-augmentation-in-treatment-resistant-obsessive-compulsive-disorder-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T14:07:51Z","timestamp":1748700471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373836-role-of-methylphenidate-augmentation-in-treatment-resistant-obsessive-compulsive-disorder-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.85131","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,31]]}}}